Ankündigung • Mar 30
Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026 Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio. New Risk • Feb 28
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$8.11m market cap, or US$5.77m). Ankündigung • Jan 30
Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 215,286,751
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 292,666,664
Price\Range: AUD 0.003
Security Features: Attached Options
Transaction Features: Rights Offering Board Change • Jan 09
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent & Non-Executive Director Paul Kasian was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 02
Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 199,086,664
Price\Range: AUD 0.003
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 134,246,669
Price\Range: AUD 0.003
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Board Change • Nov 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 15
Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 199,086,876
Price\Range: AUD 0.003
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 134,246,457
Price\Range: AUD 0.003
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Ankündigung • Sep 29
Biotron Limited, Annual General Meeting, Nov 17, 2025 Biotron Limited, Annual General Meeting, Nov 17, 2025. New Risk • Apr 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Market cap is less than US$10m (AU$3.32m market cap, or US$2.07m). Minor Risk Revenue is less than US$5m (AU$1.8m revenue, or US$1.1m). Ankündigung • Feb 21
Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 270,714,829
Price\Range: AUD 0.01 New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$9.02m market cap, or US$5.67m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). New Risk • Nov 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.3m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$15.3m market cap, or US$9.98m). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Ankündigung • Nov 28
Biotron Limited Announces Board Retirement Dr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018. New Risk • Nov 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$19.0m market cap, or US$12.3m). Ankündigung • Oct 22
Biotron Limited, Annual General Meeting, Nov 28, 2024 Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australia New Risk • Aug 31
New major risk - Negative shareholders equity The company has negative equity. Total equity: -AU$244k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$23.5m market cap, or US$15.9m). New Risk • Feb 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.7m free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$62.3m market cap, or US$40.7m). Ankündigung • Oct 20
Biotron Limited, Annual General Meeting, Nov 22, 2023 Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters. New Risk • Aug 26
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: AU$1.4m (US$918k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.5% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$918k). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (AU$28.0m market cap, or US$17.9m). New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$1.9m). Market cap is less than US$100m (AU$26.2m market cap, or US$16.8m). Ankündigung • Nov 16
Biotron Limited, Annual General Meeting, Nov 16, 2022 Biotron Limited, Annual General Meeting, Nov 16, 2022, at 11:01 E. Australia Standard Time. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • May 30
Biotron Limited Receives Positive U.S. Food and Drug Administrations Guidance for COVID-19 Clinical Program The Directors advised that Biotron Limited has received guidance from the U.S. Food and Drug Administrations or development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA's guidance was received in written response to Biotron's pre-IND briefing package and request in March 2022, which included an overview of preclinical and (HIV) clinical development, and specific questions relating to regulatory requirements for progression to filing an investigational new drug (`IND') application for the COVID-19 indication. Biotron sought guidance on the design of a proposed Phase 2 clinical trial in recently diagnosed COVID-19 infected individuals and assurance that the preclinical data package and manufacturing processes were sufficient to support this next stage of clinical development. The FDA response gives clear indication of the Agency's interest in this novel drug target that combines direct antiviral effect and beneficial immunomodulatory activities. Recent animal studies conducted at the Scripps Institute in San Diego have demonstrated that the drug is protective of disease progression and the cytokine storm that is linked to development of severe respiratory disease. BIT225 rapidly reduced viral loads in the lungs of infected animals treated before or following SARS-CoV-2 infection. With this guidance and acceptable trial design in hand, the Company will now determine its capital requirements for the COVID-19 clinical program and seek funding from potential partners and non-equity funding sources. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Nov 27
Biotron Limited Announces Its Lead Clinical Asset, BIT225, Demonstrated Substantial and Clinically Meaningful Efficacy Against SARS-CoV-2 in A Series of Animal and Cell-Based Studies Performed At the Scripps Research Institute, La Jolla, CA, USA Biotron Limited announced that the Company's lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed at The SCRIPPS Research Institute, La Jolla, CA, USA. BIT225 was tested in a COVID-19 mouse model (K18-hACE2). These mice have been engineered to be infectable by SARS-CoV-2 which then produces a range of pathologies including pulmonary disease. This model is routinely used to assess the ability of drugs to target SARS-CoV-2 and treat COVID-19 disease. The study in the COVID mice showed that BIT225 given orally (by mouth) significantly reduced virus load in the lungs of treated mice when compared with control mice that were given drug-free control material (known as vehicle control). There was also a reduction in virus in the blood. The reduction in virus was dose-dependent - i.e. reduction in viral load was greater at the higher dose. Increased levels of pro-inflammatory cytokines ('cytokine storm') are linked to severe illness and death in people infected with SARS-CoV-2 virus. Controlling this cytokine storm is essential for successful treatment of COVID-19. BIT225 significantly reduced all assayed pro-inflammatory cytokines and chemokines, including IL-6, IL-1a, IL-1ß, TNF-a, TGF-ß and MCP-1, in the lungs and blood of BIT225- treated mice compared to control mice. During the course of infection with SARS-CoV-2, K18 mice generally develop severe disease that is reflected in the loss of body weight. The animals treated with BIT225 did not lose weight throughout the study and, in fact, significantly increased their weight in line with growth expectations of the age of the animals. The impact of BIT225 on the proinflammatory cytokines and on overall health, indicated by preventing loss of body weight, indicates clinically significant benefit of BIT225. In addition to the in vivo animal study, BIT225 was tested in an in vitro study in cell cultures to assess the ability of the drug to inhibit the highly infectious delta strain. The data showed that BIT225 reduced the delta virus in the cell cultures by more than 99.99% (over 4 logs reduction). The in vivo study demonstrates that BIT225 is highly effective antiviral agent and protects the animals from severe disease. The in vitro study demonstrates that BIT225 is also active against the highly infectious delta strain of SARS-CoV-2. BIT225 belongs to a new class of antiviral drugs known as viroporin inhibitors. It targets key viral-encoded proteins known as viroporins that are central to establishing and maintaining infections through modulation of the body's immune system. BIT225 is Biotron's lead antiviral clinical-stage, investigational, small molecule antiviral drug. It is an oral drug, suitable for once-a-day dosing and has a well characterised safety profile. The drug has been evaluated in nine clinical trials involving healthy volunteers, patients with HIV-1 infection, patients co-infected with Hepatitis C virus (HCV) and HIV-1 and patients with HCV (as monotherapy and in combination with pegylated interferon-alfa and ribavirin). Formal pre-clinical studies have assessed safety over 24 weeks of dosing. Recently the Company commenced two Phase 2 HIV-1 trials in Australia and Thailand to assess the impact of BIT225 on the HIV-1 reservoir and key markers of improved health outcomes. Biotron is now in discussions with its USA advisors and consultants to expedite progression of BIT225 into human trials for treatment of SARS-CoV-2 infection. The Company has sufficient drug product on hand after recently completing the manufacture of several kilograms of additional clinical grade (cGMP) drug. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.